Mestag Therapeutics
UK - CambridgeBiotechnology
Focus: Mestag Therapeutics is a UK-based biotech company specializing in fibroblast biology for antibody discovery, leveraging a proprietary platform to generate novel therapeutic antibodies. Founded in 2016 and now public, the company operates as a pre-revenue or early-stage platform biotech with minimal disclosed commercial traction.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Total Funding
$45M
Open Jobs
0
About Mestag Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Mestag Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MST-0312
Solid MalignanciesClinical Trials (1)
NCT07610941Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies
Phase 1Help build intelligence for Mestag Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.